RSV · Kenya

Kenya weighs its best defence against RSV to protect babies before birth 

Respiratory syncytial virus (RSV) fills Kenya’s paediatric wards every year.   During World RSV Awareness Week, paediatricians, obstetricians, researchers and immunisation managers joined a ninety-minute Zoom session hosted by the Ministry of Health through the National Vaccines and Immunization Program (NVIP), titled “Understanding Respiratory Syncytial Virus (RSV) Disease in Kenya: Early Recognition, Prevention and Management”.  RSV […]

Respiratory syncytial virus (RSV) fills Kenya’s paediatric wards every year.  

During World RSV Awareness Week, paediatricians, obstetricians, researchers and immunisation managers joined a ninety-minute Zoom session hosted by the Ministry of Health through the National Vaccines and Immunization Program (NVIP), titled “Understanding Respiratory Syncytial Virus (RSV) Disease in Kenya: Early Recognition, Prevention and Management”. 

RSV is a common virus that rarely troubles healthy older children for long, but it can be deadly in babies under six months. For the first time, it is becoming preventable, either by vaccinating mothers during pregnancy or by giving antibodies directly to infants. 

A leading cause of childhood pneumonia 

Dr Bryan Nyawanda, a Senior Research Scientist at the Kenya Medical Research Institute (KEMRI), highlighted the burden of disease. The PERCH study, conducted across seven countries including Kenya, attributed an estimated 31 per cent of radiographically confirmed severe childhood pneumonia cases to RSV. Viruses together accounted for 61 per cent. 

He stressed that the figure measures disease caused by RSV, not the share of children whose swabs happened to test positive. It also comes from all seven countries combined, not Kenya alone. Even so, he said, it shows that RSV is not “a minor incidental finding in young children with pneumonia” but “one of the major causes that we need to prevent.” 

The youngest babies carry the heaviest load. Data from Kilifi showed that about 62 per cent of RSV-positive childhood pneumonia involved children aged six months or younger. That pattern held before, during and after the COVID-19 pandemic, which means protection has to arrive very early to be useful. 

Preliminary national estimates for 2021 to 2025 combine surveillance data with adjustments for health-seeking behaviour. They point to more than a million medically attended cases a year, about 760,000 cases that never reach a health facility, roughly 26,000 hospitalisations and about 80,000 severe cases outside hospital. 

Dr Nyawanda estimated between 600 and 2,800 deaths annually, with severe hospitalised disease concentrated in the first three to six months of life. 

A virus without a fixed season 

Long-term surveillance shows that RSV subgroups A and B circulate together, and the dominant one changes from season to season. The pattern also differs by place. In Kilifi, epidemics typically peak around February and last about 22 weeks. In Siaya they peak around June and run for about 18 weeks. Nairobi shows no clearly defined season at all. 

A recent Kilifi analysis found that the pandemic shifted the onset of epidemics by a month or two, although the change was not statistically significant. RSV positivity among hospitalised children stood at about 25 per cent before the pandemic and fell to 18 per cent during it. It had recovered to 19 per cent afterwards, drifting back towards its old rhythm. 

Dr Nyawanda recommended year-round prevention, warning that planning around a single national RSV season could “mistime protection in some counties.” He closed by describing RSV as “predictable enough to plan for,” “serious enough to prioritise” and, increasingly, preventable. 

Dr Wesley Mugambi, a Program Officer at NVIP, reached the same view from a programme angle. Joking that Kenya’s weather has become hard to read, he argued that a year-round approach would mean fewer missed opportunities and simpler delivery. 

He also placed Kenya in a global frame: more than 30 million cases and over three million hospitalisations a year in children under five, and more than 100,000 deaths, about 97 per cent of them in low and middle-income countries. Modelled estimates for Kenya run to between about 2,000 and almost 4,000 deaths a year in that age group, concentrated in early infancy. 

What RSV looks like at the bedside 

Dr Christine Chege, a Paediatrician representing the Kenya Paediatric Association (KPA), turned to the clinic. In babies and young children, she explained, a first RSV infection usually goes straight to the lower respiratory tract and causes bronchiolitis or pneumonia. In very young and premature infants it can trigger apnoea, pauses in breathing that lead to low oxygen and sometimes sudden death. 

Older children, whose earlier infections have given them some protection, tend to get coughs, runny noses and occasionally ear or sinus infections. Because immunity fades, reinfection is common, though each episode is usually milder than the last. 

Most health workers in Kenya cannot run a PCR test, so Dr Chege offered a bedside rule of thumb in Kiswahili: “When you have makamasi kwa kifua, so makamasi everywhere, makamasi in the nose, makamasi kwa kifua, that is RSV.” Makamasi, she explained, means mucus. 

She listed the babies at highest risk as those who are premature or under six months, children with chronic lung or heart disease, and those with weakened immunity, including HIV-exposed infants and children with Down syndrome. Babies exposed to poverty, second-hand smoke or high altitude are also more vulnerable. 

There is no specific treatment, so care is supportive. “Babies are obligate nasal breathers,” she said, so the nose should be cleared gently by suction. Fluids should be given intravenously if a breathless baby cannot swallow, nebulised saline can loosen mucus plugs, and oxygen should be stepped up as needed, from nasal prongs to masks and, where available, CPAP or high-flow nasal cannula. 

She set the threshold for concern at an oxygen saturation below 95 per cent, because waiting for 90 leaves little time to act. Where RSV cannot be confirmed, she advised clinicians to apply the World Health Organization pneumonia algorithm so that no bacterial pneumonia is missed. 

Large respiratory droplets settle on surfaces, and the virus can survive for hours on hands. “We cannot say the government is not giving us prevention when we are not washing our hands,” Dr Chege said bluntly. Where isolation is impossible, she urged hospitals to nurse RSV patients together in one room. 

The case for vaccinating mothers 

Dr Grace Kanyi, an Obstetrician-Gynaecologist representing the Kenya Obstetrical and Gynaecological Society (KOGS), made the case by pointing to Kenya’s own history with the tetanus-diphtheria (TD) vaccine. It has been given to pregnant women for decades and helped the country be validated as having eliminated neonatal tetanus, following a pre-validation exercise in Narok County in 2017 and confirmation in 2018. 

According to these specialists, when a mother is vaccinated, her immune system produces IgG antibodies that peak two to four weeks later and cross the placenta to protect the baby through its first months. Antibodies in breast milk, particularly the IgA in colostrum, guard the gut and airways. That is why she urged mothers to begin breastfeeding within an hour of birth and to breastfeed exclusively for six months. “Maziwa ya mama is the best way to go,” she said. 

The maternal RSV vaccine is a single dose recommended from 28 weeks of pregnancy. Dr Kanyi said it has been shown to be up to 82 per cent effective against severe disease in infants in the first 90 days, and about 69 per cent effective up to six months. 

In Argentina, for example, maternal vaccination was about 71 per cent effective against RSV hospitalisation in young infants. In Chile, an infant monoclonal antibody was about 76 per cent effective. The World Health Organization recommends that countries consider either the maternal vaccine or the infant antibody nirsevimab, depending on their delivery systems, and Gavi’s 6.0 strategy lets eligible countries seek support for maternal RSV vaccine introduction. 

In Kenya, the public health system has fewer than 90 neonatal intensive care beds. Dr Kanyi invited participants to imagine how many children could be spared severe illness, NICU admission, oxygen therapy and hospital bills “from this single vaccine.” 

The maternal RSV vaccine is not yet part of Kenya’s routine schedule. TD and COVID-19 vaccines are available to pregnant women in the public sector, and influenza vaccine is offered privately. RSV vaccination remains under consideration while local evidence on burden, cost and feasibility is gathered. 

The health worker is the deciding voice 

Dr Kanyi shared survey findings that 95 per cent of pregnant women value maternal vaccines, and that about six in every ten will accept one simply because their health worker recommends it. She told clinicians, community health promoters, nurses and midwives alike that “your recommendation is the strongest driver.” 

She asked them to treat every antenatal visit as a chance to vaccinate. That means checking the Mother and Child Handbook, asking them how many times they have been pregnant, and looking at the immunisation chart. Above all, it means not sending the mother elsewhere. “If we refer the mother elsewhere to receive this vaccine, most of the time they’ll be lost to follow-up,” she warned. 

Women’s worries, she said, are usually about the baby rather than themselves. Mothers rarely ask whether a vaccine is safe for them and instead ask “is it safe for my baby?” Her advice was to listen, acknowledge the concern, and then explain the science in simple language, including the local dialect. The RSV vaccine is not a live vaccine, so it cannot give the mother the infection. The most common side effect is soreness at the injection site, and studies have not shown an increased risk of congenital anomalies. “It helps to frame the benefit around the baby,” she said. 

Dr Mugambi was candid that a good vaccine is only as good as the system that delivers it. Antenatal clinics are the natural platform because that is where TD is already given, although attendance falls with each subsequent visit. He argued for concentrating on the early contacts, when the most mothers can be reached. 

He also pointed to wide gaps between counties. TD antenatal coverage is about 45 per cent in Nyamira against around 80 per cent in several others. The same drop shows within the TD schedule itself, which Dr Kanyi described as falling from about 93 per cent uptake for the first dose to about 19 per cent for the fifth. Vaccines, Dr Mugambi observed, “don’t perform the same across the entire country.” 

Placing a vaccine in a clinic is therefore not enough. Community health promoters should identify and mobilise pregnant women, outreach should target low-performing areas, and coverage data should be broken down by facility, age and geography so that weak spots can be fixed. 

For now, the question is when and how Kenya will add RSV protection for newborns. Many participants asked in the webinar chat whether it could be combined with the existing TD injection to reduce the number of jabs, a sign of how closely health workers are already thinking about delivery. 

Field reflection

There is no specific treatment, so care is supportive. “Babies are obligate nasal breathers,” she said, so the nose should be cleared gently by suction. Fluids should be given intravenously if a breathless baby cannot swallow, nebulised saline can loosen mucus plugs, and oxygen should be stepped up as needed, from nasal prongs to masks and, where available, CPAP or high-flow nasal cannula.